Semaglutide (Wegovy) — coverage for weight management, cardiovascular event prevention, and MASH
Customize your policy alerts
Sign up for mhn Policy HNCA.CP.CPA.352 alerts
Get alerted when Policy HNCA.CP.CPA.352 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, prior authorization requirements, dosing limits, and renewal rules for Wegovy (semaglutide) for weight management, cardiovascular event prevention, and metabolic dysfunction-associated steatohepatitis for Health Net of California members.
Added FDA-approved indication for metabolic dysfunction-associated steatohepatitis (MASH) with associated criteria and appendix updates.
Updated cardiovascular event (CVE) indication per FDA labeling including age revision to ≥18 years and limitations of use per prescribing information.
Added requirement that member must be actively enrolled in a weight loss program for at least 6 months prior to GLP-1 therapy and documentation requirements for program and baseline/current weight.
Excluded compounded medications and samples from coverage.
Defined continued therapy positive response criterion as ≥5% weight loss from baseline for adults (and BMI criteria for pediatrics).
Coverage Criteria and Indications
Initial Therapy — Weight Management
Covered when ALL of the following are met for Initial Approval — Weight Management
For members switching from Zepbound to Wegovy due to weight-loss plateau, the prior BMI threshold may be used if gap in therapy ≤ 60 days.
Age/BMI requirement
- With T2DM: Age ≥ 18 years
- Without T2DM: Age ≥ 12 years
Initial Therapy — Cardiovascular Event Prevention
Covered when ALL of the following are met for Cardiovascular Event Prevention (CVE)
Initial Therapy — MASH
Covered when ALL of the following are met for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Continuation Therapy — Weight Management
Covered when ALL of the following are met for Continuation/Renewal — Weight Management
Continuation Therapy — Cardiovascular Event Prevention
Covered when ALL of the following are met for Continuation/Renewal — Cardiovascular Event Prevention
Continuation Therapy — MASH
Covered when ALL of the following are met for Continuation/Renewal — MASH
Initial and ongoing coverage criteria
Covered when ALL of the following are met
See dosing schedule for escalation and maintenance doses
If patients do not tolerate a dose during escalation, consider delaying escalation for 4 weeks
If contraindicated, therapy is not authorized
Initial and Continued Approval Themes
Covered when ALL of the following are met per indication-specific criteria (weight loss, CVE, MASH):
Program should be Health Net approved or recommended by the prescriber
Tolerance to maintenance dose to be documented after specified therapy duration
Continued approval duration and timing specified per indication
Applies where indicated in policy revisions
Noninvasive test examples moved to Appendix F
Compounded medications and samples are excluded from coverage. The policy explicitly states that compounded products and samples are not covered and that claims for such products may be denied or redirected per policy revisions.
Requests for non‑FDA approved indications that are not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety per the off‑label use policy CP.CPA.09 or evidence of coverage. Coverage may be denied if the requested use is outside FDA‑approved indications and unsupported by those referenced policies.
Compounded semaglutide products and samples are excluded from coverage. The policy notes that members who received compounded products or certain NovoCare® self‑pay Wegovy may be redirected to initial criteria or otherwise ineligible for coverage if documentation does not meet policy requirements.
Use of Wegovy concurrently with other semaglutide‑containing products, any other GLP‑1 receptor agonist, or Rezdiffra™ (for the MASH indication) is considered not authorized for coverage. The policy requires that Wegovy not be prescribed with these other agents and lists concurrent therapy as a denial risk.
Per Endocrine Society guidance cited in the policy, a weight loss of <5% after 3 months of therapy indicates the medication is ineffective. The guideline recommends discontinuation of the medication and consideration of alternative therapies in such cases.
Codes referenced in this clinical policy are provided for informational purposes only. Inclusion of codes in the policy does not guarantee coverage; claims may be denied if submitted documentation does not meet the medical necessity criteria described in the policy.
Coding, Dosing, and Thresholds
| Ozempic (semaglutide) dosing 0.25–2 mg/week | Alternative semaglutide formulation and dosing limits (max 2 mg/week) |
| Rybelsus (semaglutide) formulations R1/R2 | Oral semaglutide dosing regimens and maximum doses (R1 14 mg/day; R2 9 mg/day) |
| Trulicity (dulaglutide) dosing 0.75–4.5 mg/week | Alternative GLP‑1 dosing limits (max 4.5 mg/week) |
| Liraglutide (Victoza) dosing 0.6–1.8 mg/day | Alternative GLP‑1 (Victoza) dosing limits (max 1.8 mg/day) |
Prior Authorization, Documentation, and Operational Rules
Prior authorization required with complete documentation
Prior authorization is required. Submit documentation that the member meets BMI and age requirements, has been actively enrolled in an approved weight loss program for ≥6 months and will continue it, baseline and current height and weight within 30 days, follows the titration schedule and dosing limits (including maintenance dose limits), and is not prescribed Wegovy concurrently with other semaglutide-containing products or other GLP‑1 receptor agonists.
- BMI per Appendix B
- Active weight loss program enrollment ≥6 months and plan to continue
- Baseline and current height/weight within 30 days
- Dose escalation per weeks 1–16 and maintenance/maximum dose limits
- No concurrent semaglutide-containing products or other GLP‑1 receptor agonists
Therapeutic alternatives may require prior authorization
Prior authorization may be required for therapeutic alternatives listed in Appendix G. The formulary’s preferred alternatives (other GLP‑1 agents) are listed in Appendix G and may themselves require prior authorization.
- Appendix G lists preferred alternative therapies and notes they may require prior authorization
- Examples and dosing limits for alternatives are provided in the therapeutic alternatives table
PA required; C9399 and J3490 listed as informational codes
Prior authorization is required and must include documentation that the request meets the indication‑specific criteria. HCPCS codes C9399 and J3490 are referenced in the policy as informational billing codes related to drug reporting.
Required prior GLP‑1 trials for members with T2DM
For members with concurrent type 2 diabetes mellitus, prior trials of other GLP‑1 agents are required: failure of ≥3 consecutive months each of Ozempic (or Rybelsus), Trulicity, and Liraglutide is required unless clinically significant adverse effects occur or all are contraindicated.
- Failure of ≥3 consecutive months for each agent: Ozempic or Rybelsus, Trulicity, and Liraglutide
- Intolerance due to common GI side effects is not acceptable justification
Preferred alternatives and dosing limits listed
Preferred therapeutic alternatives and dosing limits are specified and may influence authorization decisions; the policy’s therapeutic alternatives table lists other GLP‑1 agents and their dosing limits.
- Alternatives include Ozempic (0.25–2 mg/week), Rybelsus (oral formulations), Trulicity (up to 4.5 mg/week), and liraglutide (up to 1.8 mg/day)
- Dose limits per agent are provided and considered when evaluating alternatives
Preferred GLP‑1 trial requirement for concurrent T2DM
For members with concurrent T2DM the policy requires trials of preferred GLP‑1 agonists (e.g., Rybelsus, Trulicity, liraglutide) prior to Wegovy or redirection to preferred agents per the concurrent diabetes criteria.
- Policy revisions add redirection to preferred GLP‑1 agonists for concurrent diabetes
- Rybelsus, Trulicity, and liraglutide are named as preferred agents
Submit office notes, labs, and weight‑program documentation
Providers must submit supporting documentation with the prior authorization request, including office chart notes, labs, or other clinical information that documents BMI per Appendix B, active participation in an approved weight loss program for ≥6 months and intent to continue, and baseline and current height/weight within the last 30 days.
- BMI documentation as defined in Appendix B
- Weight loss program name/example and confirmation of ≥6 months participation
- Baseline and current height and weight within 30 days
- Planned follow-up visits to assess adherence and response
MASH documentation: biopsy or combined noninvasive assessments
For MASH indications, submit documentation confirming stage F2–F3 fibrosis by liver biopsy within the last 3 years, or both serum‑ and imaging‑based assessments within the last 6 months (examples in Appendix F), and prescriber specialty involvement or consultation.
- Liver biopsy showing F2–F3 fibrosis within 3 years OR serum‑ and imaging‑based assessments within 6 months (e.g., FIB‑4, ELF, VCTE/MRE/MRI‑PDFF)
- Prescription by or consultation with a hepatologist or gastroenterologist
If recent label change or off‑label use, follow formulary/off‑label policies
If the drug’s FDA label has changed within the last 6 months or the requested use is not listed in Section III, follow the formulary/no‑coverage or off‑label use policies (CP.CPA.190 or CP.CPA.09) and provide supporting documentation per those policies.
- Refer to CP.CPA.190 (no coverage/non‑formulary) or CP.CPA.09 (off‑label) as directed
- Provide evidence supporting the requested off‑label use or new indication
Document ≥6 months weight‑loss program enrollment (name and start date when required)
Document enrollment in a weight loss program for at least 6 months prior to initiating GLP‑1 therapy; include the program name and start date when requested by the policy, and verify the member will continue the behavioral program during treatment.
- Active participation for ≥6 months in a Health Net approved program (e.g., Weight Watchers, Active&Fit) or prescriber‑recommended program
- Program name and start date as required by recent policy updates
- Attestation that the member will continue the program while on Wegovy
MASH diagnostic documentation must meet revised lookback and Appendix F tests
For MASH, ensure diagnostic documentation meets the updated biopsy lookback period (3 years) or approved noninvasive imaging/biomarker evidence per Appendix F and include prescriber attestation of specialty management.
- Biopsy within 3 years OR both serum‑ and imaging‑based assessments within 6 months (see Appendix F for examples)
- Prescriber (hepatologist/gastroenterologist) involvement or consult attestation
Coverage may be denied for non‑FDA indications or excluded benefits
Coverage may be denied if the requested use is for a non‑FDA approved indication not addressed in this policy without sufficient off‑label support, or if the member’s benefits exclude weight loss drugs or compounded medications/samples.
- Non‑FDA approved indications require support per CP.CPA.09 or evidence of coverage
- Check member benefits for coverage of weight loss drugs
- Compounded medications and samples are excluded from coverage
Do not co‑prescribe with other semaglutide/GLP‑1 agents or Rezdiffra
Do not prescribe Wegovy concurrently with other semaglutide‑containing products, any other GLP‑1 receptor agonist, or with Rezdiffra for MASH; concurrent therapy risks denial of coverage.
- Wegovy must not be prescribed with other semaglutide products or other GLP‑1 receptor agonists
- For MASH, Wegovy must not be prescribed concurrently with Rezdiffra
Non‑FDA indications require off‑label policy support
Requests for non‑FDA approved indications that are not addressed in this policy may be denied unless supported by the off‑label use policy (CP.CPA.09) or other evidence of efficacy and safety.
- Provide documentation per CP.CPA.09 when requesting coverage for off‑label uses not listed in this policy
Compounded products, samples, and NovoCare® self‑pay may be excluded or redirected
Compounded semaglutide products, samples, or NovoCare® self‑pay Wegovy may trigger redirection to initial criteria or be excluded from coverage; members who received these may be redirected to meet initial criteria first.
- Compounded medications and samples are excluded from coverage
- Members who received compounded semaglutide or NovoCare® self‑pay Wegovy may be redirected to initial criteria
Background and Policy Scope
Semaglutide (Wegovy) is a glucagon‑like peptide‑1 (GLP‑1) receptor agonist indicated in combination with diet and exercise for chronic weight management in adults and pediatric patients aged ≥12 years, for reduction of major cardiovascular events in adults with established cardiovascular disease and overweight/obesity, and for treatment of metabolic dysfunction‑associated steatohepatitis (MASH) with moderate–advanced fibrosis (F2–F3). The policy notes that coadministration with other semaglutide products or other GLP‑1 receptor agonists is not recommended and may be a basis for denial.
Definitions and Clinical Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.